A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia

Trial Profile

A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients With Immunosuppressive-Therapy Refractory Thrombocytopenia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Eltrombopag (Primary)
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2020 as reported by ClinicalTrials.gov.
    • 02 Sep 2015 According to Ligand Pharmaceuticals media release, Revolade received EU approval as First-in-class Therapy for patients with severe anaplastic anemia.
    • 24 Jul 2015 According to Ligand pharmaceuticals Incorporated media release, CHMP of the European Medicine Agency adopted a positive opinion for Revolade.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top